Darleukin, Fibromun
PHL19IL2TNFNMSC04/19
Phase 2 small_molecule active
Quick answer
Darleukin, Fibromun for Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines. is a Phase 2 program (small_molecule) at Philogen S.p.A. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Philogen S.p.A.
- Indication
- Patients with high-risk, locally advanced (non-metastatic, node negative, single or multifocal), Basal Cell Carcinoma (BCC) or cutaneous Squamous Cell Carcinoma (cSCC) amenable to intratumoral injection, not eligible to surgery or radiation therapy according to the evaluation of a local interdisciplinary tumor board or who refuse surgery or radiation therapy and for whom a histological evaluation is available according to international guidelines.
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active